Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTech has the GF Score of 74, which implies that the company
is
Likely to have average performance.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Sanara MedTech
is
Likely to have average performance.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Sanara MedTech (NAS:SMTI) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Sanara MedTech GF Score Related Terms
SMTI vs EMBC, KRMD, UTMD: GF Score Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's GF Score distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's GF Score falls into.
Sanara MedTech (SMTI) has a GF Score of 74 as of Jul. 23, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sanara MedTech and its competitors. This is 16% above median its historical median of 64.00. Over the past decade, Sanara MedTech's GF Score has ranged from 49.00 to 82.00.
Is Sanara MedTech's GF Score too high?
Sanara MedTech's current GF Score of 74 is 16% above median its 10-year median of 64.00. Over the past 10 years, this metric has ranged from a low of 49.00 to a high of 82.00. Overall, Sanara MedTech has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's GF Score compare to EMBC and KRMD?
Sanara MedTech's GF Score of 74 can be compared against companies in the Medical Devices & Instruments industry. Historically, Sanara MedTech's own GF Score has ranged from 49.00 to 82.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Sanara MedTech and its competitors. Sanara MedTech's current GF Score is 74, which is 16% above median its own 10-year median of 64.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.84, compared to a current price of $25.55 — trading 44.3% below its estimated fair value. The current GF Score is 74, which is 16% above median its 10-year median of 64.00. Sanara MedTech's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current GF Score is 74 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $25.55 is trading 44.3% below its estimated GF Value™ of $45.84.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
GF Score: 74 (16% above median its 10-year median of 64.00)
GF Value™: $45.84 vs. price of $25.55 (44.3% below fair value)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
74GF Score
Get the complete analysis for SMTI
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
